Lessons for Patient Education Around Long-Acting Injectable PrEP: Findings from a Mixed-Method Study of Phase II Trial Participants

AIDS Behav. 2018 Apr;22(4):1209-1216. doi: 10.1007/s10461-017-1871-x.


This study aimed to identify patients' physical and psychosocial experiences of an investigational long-acting injectable PrEP product to aid in the development of patient and provider education materials. Twenty-eight participants of a Phase 2 safety, tolerability, and acceptability study of long-acting integrase inhibitor cabotegravir (CAB-LA) were interviewed on their physical and psychosocial experiences of the injections. Five themes emerged through a framework analysis on these interview transcripts: (1) injection-related pain is highly variable across individuals; (2) pain is more impactful after the injections than during; (3) patient anxiety is critical, but does not determine the experience of injections and decreases over time; (4) intimacy and awkwardness of gluteal injections impacts patients' experiences; (5) patient education and care strategies can mitigate the above factors. These findings can inform further sociobehavioral research within Phase 3 efficacy trials of CAB-LA, as well as patient education and provider guidance for future injectable PrEP products.

Keywords: HIV; Long-acting injectable; MSM; Patient education; PrEP; Providers.

Publication types

  • Clinical Trial, Phase II
  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • Anti-HIV Agents / administration & dosage
  • HIV Infections / drug therapy
  • HIV Infections / prevention & control*
  • Homosexuality, Male
  • Humans
  • Injections, Intramuscular
  • Integrase Inhibitors / administration & dosage*
  • Interviews as Topic
  • Male
  • Patient Acceptance of Health Care*
  • Patient Education as Topic*
  • Pre-Exposure Prophylaxis / methods*
  • Pyridones / administration & dosage*
  • Qualitative Research


  • Anti-HIV Agents
  • Integrase Inhibitors
  • Pyridones
  • cabotegravir